{"doi":"10.3389/fneph.2023.1168614","title":"Case Report: Immune checkpoint inhibitor–induced multiorgan vasculitis successfully treated with rituximab","abstract":"Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer. ICIs have a unique side effect profile, generally caused by inflammatory tissue damage, with clinical features similar to autoimmune conditions. Acute kidney injury from ICIs has been well studied; incidence ranges from 1% to 5%, with higher incidence when combination ICI therapies are used. Although the overall reported incidence of ICI-associated glomerulonephritis is less than 1%, vasculitis is the most commonly reported ICI-related glomerulonephritis. Other biopsy findings include thrombotic microangiopathy, focal segmental glomerulosclerosis, minimal change disease, and IgA nephropathy with secondary amyloidosis. We report a case in which a woman previously treated with the PD-L1 inhibitor durvalumab for locally advanced non-small cell lung cancer with pre-existing antineutrophil cytoplasmic (anti-PR3) antibody who later developed multi-organ vasculitis after ICI exposure, which was successfully treated with rituximab, with continued cancer remission for 3 years.","journal":"Frontiers in Nephrology","year":2023,"id":367193,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9599,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1069202,"name":"Naszrin Arani","orcid":null,"position":1,"is_corresponding":false},{"id":1124819,"name":"Vishnu P. Parvathareddy","orcid":null,"position":2,"is_corresponding":false},{"id":356841,"name":"Amanda Tchakarov","orcid":"0000-0001-6281-7786","position":3,"is_corresponding":false},{"id":356840,"name":"Maen Abdelrahim","orcid":"0000-0002-6631-5035","position":4,"is_corresponding":false},{"id":60963,"name":"María E. Suarez‐Almazor","orcid":"0000-0001-5381-5797","position":5,"is_corresponding":false},{"id":24639,"name":"Jiexin Zhang","orcid":"0000-0001-9526-6730","position":6,"is_corresponding":false},{"id":228170,"name":"Don L. Gibbons","orcid":"0000-0003-2362-3094","position":7,"is_corresponding":false},{"id":227923,"name":"John V. Heymach","orcid":"0000-0001-9068-8942","position":8,"is_corresponding":false},{"id":236012,"name":"Mehmet Altan","orcid":"0000-0001-9229-156X","position":9,"is_corresponding":false},{"id":356843,"name":"Ala Abudayyeh","orcid":"0000-0002-5813-6299","position":10,"is_corresponding":false},{"id":1124818,"name":"Sehrish Qureshi","orcid":null,"position":0,"is_corresponding":true}],"reference_count":29,"raw_metadata":null,"created_at":"2026-07-19T01:15:12.215513Z","pmid":"37675380","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}